---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Pathophysiology"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Pathophysiology. Topics: MeCP2 expression in the nervous system, MeCP2 as a transcriptional regulator, Loss of function and location of pathogenic variants, Neuropathology: reduced brain and neuronal size without neuronal death, and 5 further topics. 9 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/pathophysiology"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### MeCP2 expression in the nervous system

> “MeCP2 is an abundant nuclear protein that was originally identified in a screen for proteins with methyl-DNA-specific binding activity. It is ubiquitously expressed throughout all human tissues, but is particularly abundant within neurons”
> “In the central nervous system (CNS), MeCP2 is expressed at low levels prenatally, but progressively increases during neuronal maturation and synaptogenesis reaching its peak in mature, post-migratory neurons, suggesting a role for MeCP2 in maintaining neuronal maturation, activity and plasticity”

Source: [Kyle et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5830535/)

> “MECP2 plays a particularly important role in synaptic development, neuronal maturation, and epigenetic regulation in the brain.”

Source: [Choi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12428351/)

<a id="topic-2.2.1.4-2"></a>

### MeCP2 as a transcriptional regulator

> “These findings have led to a model wherein MeCP2 serves as a bridge between methylated DNA and the corepressor complex, anchoring the NCoR1/SMRT complex to DNA via its NID and MBD, respectively. It is hypothesized that disruption of this bridge leads to histone hyperacetylation and an open chromatin state, thereby increasing the transcription of target genes”

Source: [Kyle et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5830535/)

> “Scientists know that lack of a properly functioning MeCP2 protein disturbs the function of mature brain cells, but they do not know the exact mechanisms by which this happens.”

Source: [NINDS](https://www.ninds.nih.gov/health-information/disorders/rett-syndrome)

<a id="topic-2.2.1.4-3"></a>

### Loss of function and location of pathogenic variants

> “It has been suggested that pathogenic variants result in loss of protein function; some functional studies show that pathogenic MECP2 variants affect the MBD or TRD domains of the abnormal protein, depending on the location of the variant”
> “The majority of pathogenic variants occur in the region encoding the methyl binding domain (MBD, exons 3 and 4; amino acids 90-174 of the MeCP2 e2 isoform), affecting the ability of the MeCP2 protein to bind to target DNA.”

Source: [Kaur and Christodoulou (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1497/)

> “eight common mutations (R106W, R133C, T158M, R168X, R255X, R270X, R294X, R306C) account for more than 60% of typical RTT individuals.”

Source: [Neul et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2677974/)

<a id="topic-2.2.1.4-4"></a>

### Neuropathology: reduced brain and neuronal size without neuronal death

> “Studies employing neuroimaging, neuropathology, neurochemistry and animal models show reductions in brain size and global decreases in neuronal size, as well as alterations in multiple neurotransmitter systems.”

Source: [Gold et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39511247/)

> “Reduced brain volume is largely due to small neuronal body size and a denser packing of cells, particularly in layers III and V of the cerebral cortex, thalamus, substantia nigra, basal ganglia, amygdala, cerebellum and hippocampus”
> “Patients also have reduced dendritic arborization, indicative of a delay in neuronal maturation”

Source: [Kyle et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5830535/)

> “Neuronal death is absent suggesting that this is not a neurodegenerative disorder.”

Source: [Guy et al. (2007)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7610836/)

<a id="topic-2.2.1.4-5"></a>

### Neuronal and glial cell types affected

> “Cortical GABAergic neurons exhibit approximately 50% higher MECP2 expression level than non-GABAergic neurons, suggesting that MECP2 deficiency has a more significant effect on GABAergic neurons than on other neurons”
> “MECP2 deficiency in GABAergic neurons leads to the loss of multiple functions such as social behavior, learning, memory, motor function, stereotyped behaviors, and sensorimotor gating.”

Source: [Choi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12428351/)

> “Moreover, deletion of MeCP2 from glial cells induces a RTT-like phenotype, and re-introducing MeCP2 to astrocytes of Mecp2 null mice using GFAP-Cre improves symptoms and restores dendritic morphology”

Source: [Kyle et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5830535/)

<a id="topic-2.2.1.4-6"></a>

### X-chromosome inactivation and cellular mosaicism in females

> “Female heterozygous RTT patients are mosaic, allowing some cells to express the mutant MECP2, while the others express the wild-type allele. XCI can be skewed preferentially so the mutant X chromosome is more or less expressed than the wild type, resulting in either a relatively more severe or milder presentation of RTT, respectively”

Source: [Kyle et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5830535/)

> “Because the MECP2 gene is subject to X‐chromosome inactivation (XCI), factors including MECP2 genotypic variation, tissue differences in XCI, and skewing of XCI all likely contribute to the clinical severity of individuals with RTT.”
> “The average XCI ratio in probands was slightly increased compared to their unaffected mothers (73% vs. 69%, p = .0006). Among the duos with informative XCI data, the majority of individuals with classic RTT had their paternal allele preferentially inactivated (n = 180/220, 82%).”

Source: [Fang et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9034674/)

> “Although variation in XCI can explain some of the variance in severity of individuals with RTT (approximately 20%)”

Source: [Neul et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2677974/)

<a id="topic-2.2.1.4-7"></a>

### MECP2 genotype and clinical severity

> “Participants with the R133C mutation are less severely affected than those with R168X or large DNA deletions (p<0.05). Likewise, individuals with the R168X mutation are more severely affected than those with R294X and late carboxy-terminal truncating mutations (p<0.05).”
> “Individuals with R168X are less likely to walk (p=0.008), retain hand use (p=0.002), or use words (p=0.001).”

Source: [Neul et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2677974/)

> “Using a database of 1052 participants assessed over 4940 unique visits, the largest cohort of both typical and atypical RTT patients studied to date, we examined the relationship between MECP2 mutation status and measures of growth, motor coordination, communicative abilities, respiratory function, autonomic symptoms, scoliosis, and seizures over time.”
> “In contrast, p.Arg106Trp, p.Arg168X, p.Arg255X, p.Arg270X, Splice Sites, Large Deletions, Insertions, and Deletions were significantly more severe.”
> “However, clinical severity continues to become progressively worse with advancing age regardless of initial severity.”

Source: [Cuddapah et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4403764/)

<a id="topic-2.2.1.4-8"></a>

### Reversal of the phenotype after MeCP2 restoration in mice

> “Using a mouse model, we demonstrate robust phenotypic reversal, as activation of MeCP2 expression leads to striking loss of advanced neurological symptoms in both immature and mature adult animals.”
> “By contrast, five out of six symptomatic Stop/y,cre animals were rescued by TM treatment.”

Source: [Guy et al. (2007)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7610836/)

<a id="topic-2.2.1.4-9"></a>

### MECP2 dosage sensitivity

> “Activation of Mecp2 in Stop/y,cre males at this stage (bracket TM-1, Fig. 2A), prior to symptom onset, revealed toxicity associated with abrupt Mecp2 reactivation as 9 out of 17 mice developed neurological symptoms and died soon after the daily TM injection series”
> “The toxic effects resembled those caused by over-expression of an Mecp2 transgene in mice”

Source: [Guy et al. (2007)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7610836/)

> “The intersection of MDS and RTT is best described as a ‘Goldilocks paradigm’”
> “in which too much of MeCP2 (MDS) and too little (RTT) will result in a severe disease state and highlights the importance of regulating this multi-functional protein and the difficult task of potential therapeutic strategies in maintaining a narrow range of MECP2 levels.”

Source: [Ta et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8939085/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
